|
Core Binding Factors, Noggin
& Sclerostin Antibodies
|
Items |
Antigen
peptide location |
Antibody Host |
*Expected
Ab Crossreactivity |
Aff. Pure
IgG/Mab
Cat #
(100 ug) |
* Control
Peptide
Cat#
(100 ug) |
|
CBFA1
(ab #1) |
h, 17aa, mid-region |
Rb |
h, m, r |
CBFA11-A |
CBFA11-A |
|
CBFA1
(ab #2) |
m, 15aa, mid-region |
Rb |
m, r, h, ch |
CBFA12-A |
CBFA12-A |
|
CBFA2 |
h, 14aa,~CT |
Rb |
h |
CBFA21-A |
CBFA21-A |
|
CBFA3 |
h, 14aa, mid-region |
Rb |
m, r, h |
CBFA31-A |
CBFA31-A |
|
Noggin
(Ab #1) |
H/M, 15aa, ~NT |
Rb |
h, m, r |
NOGN11-A |
NOGN11-A |
|
Noggin
(Ab #2) |
H/M, 15aa, ~CT |
Ch |
m, r, h |
NOGN12-A |
NOGN12-A |
|
Noggin
pure protein |
Mouse
Recombinant purified Noggin protein,
WB +ve control, Cat # NOGN12-C, 100ul |
|
Noggin
pure protein |
Human
Recombinant purified Noggin protein, WB +ve control,
Cat # NOGN11-C, 100ul
Human Recombinant Purified Noggin protein,
Cat # NOGN15-R-5, 5ug
Human Recombinant Purified Noggin protein,
Cat # NOGN15-R-20, 20ug |
|
Sclerostin |
h, 17aa, ~CT |
Rb |
m, r, h |
SOST11-A |
SOST11-P |
|
Control Rabbit IgG |
For use in
ELISA, Western, Immunohisto. |
20009-1 (1 mg) |
Rb=rabbit; m=mouse; r=rat; h=human; s=sheep; b=bovine; ch=chicken;
d=dog; ~CT or ~NT=near C or N-terminus. EC=Extracellular; CL=Cytoplasmic
loop.
Core Binding Factors,
Noggin & Sclerostin Antibodies-General
Information
The gene noggin
encodes a member of one of at least four distinct gene families encoding
secreted polypeptides that bind to members of the transforming growth
factor-beta superfamily, such as BMP, and
inhibit the function of these signaling proteins by preventing their
interaction with receptors on the cell surface. Other antagonists with
related functions include Chordin, Follistatin,
Sclerostin and members of the DAN family. These BMP antagonists
are assumed to be diffusible and therefore potentially important in the
establishment of BMP activity gradients in vivo Although structurally
distinct, members of these gene families have in some cases similar
ligand specificity and overlapping patterns of expression, and in the
case of Chordin and Noggin these proteins apparently are capable of at
least partial compensation for each other. In addition to these multiple
secreted BMP antagonists, there are other secreted proteins whose
primary function is to overcome this antagonism. Thus, there is a highly
complex system to regulate the bioavailability and consequently the
activities of BMPs in the extracellular space.
BMP activities are modulated through gene
expression, protein processing and by interaction with antagonists. The
interplay between BMPs and their antagonists governs developmental and
cellular processes as diverse as establishment of the embryonic
dorsal-ventral axis, induction of neuronal tissue, and formation of
joints in the skeletal system and the neurogenesis in the adult brain.
Noggin inhibits BMP signaling by blocking the molecular interfaces of
the binding epitopes for both type-I and -II receptors of BMP.
BMPs are important regulators of key events
in the processes of bone formation during embryogenesis, postnatal
growth, remodeling and regeneration of the skeleton. The BMPs function
by binding to a receptor complex that is found on all normal cells and
is composed of type-I and -II receptors. The primary unit of bone
formation is osteoblast, the bone-forming cell. These osteoblast cells
respond to physical loading by transducing signals that alter gene
expression patterns. Cbfa (core binding
factor), the osteoblast specific transcription factor plays an important
role in osteoblast differentiation and function.
Cbfa1/ Runx2/
OSF2/AML3 (alternatively spliced form 507aa and 522aa in human
(chr 6p21) and 528aa or 596aa in mouse) is expressed in bone thymus,
testis but not in brain, lung, heart or kidney. It is a transcription
factor involved in osteoblastic differentiation and skeletal
morphogenesis, essential for the maturation of osteoblast and both
intramembranous and endochondral ossification. Defects in Cbfa1 are the
cause of cleidocranial dysplasia (CCD), an autosomal dominant skeletal
disorder with high penetrance and variable expressivity. It is due to
defective endochondral and intramembranous bone formation.
Cbfa 2/ Runx1/ AML 1
(11 spliced forms) a 450aa protein in rat, 451aa in mouse and 453 in
human (Chr. 21q22.3), It binds to the core site 5'-PYGPYGGT-3' of a
number of enhancers and promoters like murine leukemia virus, T-cell
receptor enhancers, expressed in all tissues except brain and heart.
Cbfa 3/ Runx3/ AML 2
(2 spliced forms), A protein 409aa long each in mouse, rat and
415aa long in human (Chr. 1p36). As Cbfa 2 it also bind to the core site
of number of enhancers and promoters, interacts with TLE1. Its DNA
binding is increased by heterodimerization. It shows subcellular nuclear
localization.
Noggin is a
homodimer (~32kDa) of two monomeric units linked together by a disulfide
bond. The monomeric precursor (232aa, human and mouse) is encoded by NOG
gene, mapped at human chromosome 17. The mature protein (28-232aa) is
secreted as a glycosylated dimer, which binds to BMPs including BMP-2,
-4 and-7. The structure of Noggin is very similar to BMP-7. Mutation in
Noggin gene leads to skeletal dysplasias characterized by joint fusions.
Sclerostin
(213aa in rat and human (chr 17q12) and 211aa in mouse) is a novel
secreted osteoclast-derived BMP antagonist with unique ligand
specificity; it negatively regulates the formation of bone by repressing
the differentiation and/or function of osteoblasts induced by BMPs.
Since sclerostin expression is confined to the bone resorbing
osteoclast, it provides a mechanism whereby bone apposition is inhibited
in the vicinity of resorption. Indicating the role of sclerostin in bone
remodeling and links bone resorption and bone apposition. Defects in
SOST are the cause of sclerosteosis, a progressive sclerosing bone
dysplasia.
All Products are for in vitro research use
only. rev 50125A
List of publications using ADI's
Antibodies to various Cbfa-Noggin related items
cbfa1
Steinert A, 2003, Chondrogenic differentiation of mesenchymal progenitor
cells encapsulated in ultrahigh-viscosity alginate Journal of
Orthopaedic Research 21, 1090-1097, IHC
Cbfa-1
Perinpanayagam ,H, 2003, Altered Cbfa1 expression and biomineralization
in an osteosarcoma cell line Journal of Orthopaedic Research, 22,
404-410, WB, UMR and B1 Cells/60 kda
Cbfa-1
Rabie ABM,, 2003 Cbfa1 couples chondrocytes maturation and endochondral
ossification in rat mandibular condylar cartilage Arch Oral Biol 49,
1009-1118, IHC, rat temporomandibular
joints, |